Literature DB >> 28583420

The Boosting Potential of Bacteria in Cancer Immunotherapy.

David C Binder1, Derek A Wainwright2.   

Abstract

Salmonella Typhimurium, engineered to express flagellin B, recently demonstrated unprecedented tumor control through a TLR-dependent mechanism. Here, we review new observations that support the potential of utilizing modified bacteria to enhance antitumor immunity. We also discuss the implications of these findings for clinical applications, including immune checkpoint blockade therapies.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28583420      PMCID： PMC5515260          DOI： 10.1016/j.molmed.2017.05.008

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  10 in total

1.  Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.

Authors:  David C Binder; Boris Engels; Ainhoa Arina; Ping Yu; James M Slauch; Yang-Xin Fu; Theodore Karrison; Byron Burnette; Christian Idel; Ming Zhao; Robert M Hoffman; David H Munn; Donald A Rowley; Hans Schreiber
Journal:  Cancer Immunol Res       Date:  2013-08       Impact factor: 11.151

2.  Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium.

Authors:  Steven A Rosenberg; Paul J Spiess; David E Kleiner
Journal:  J Immunother       Date:  2002 May-Jun       Impact factor: 4.456

3.  Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin.

Authors:  Jin Hai Zheng; Vu H Nguyen; Sheng-Nan Jiang; Seung-Hwan Park; Wenzhi Tan; Seol Hee Hong; Myung Geun Shin; Ik-Joo Chung; Yeongjin Hong; Hee-Seung Bom; Hyon E Choy; Shee Eun Lee; Joon Haeng Rhee; Jung-Joon Min
Journal:  Sci Transl Med       Date:  2017-02-08       Impact factor: 17.956

4.  Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.

Authors:  John F Toso; Vee J Gill; Patrick Hwu; Francesco M Marincola; Nicholas P Restifo; Douglas J Schwartzentruber; Richard M Sherry; Suzanne L Topalian; James C Yang; Frida Stock; Linda J Freezer; Kathleen E Morton; Claudia Seipp; Leah Haworth; Sharon Mavroukakis; Donald White; Susan MacDonald; John Mao; Mario Sznol; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  CD4+-T-cell responses generated during murine Salmonella enterica serovar Typhimurium infection are directed towards multiple epitopes within the natural antigen FliC.

Authors:  Molly A Bergman; Lisa A Cummings; Robert C Alaniz; Laura Mayeda; Ivana Fellnerova; Brad T Cookson
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

7.  Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.

Authors:  Justin Kline; Ian E Brown; Yuan-Yuan Zha; Christian Blank; John Strickler; Harald Wouters; Long Zhang; Thomas F Gajewski
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

8.  Containment of tumor-colonizing bacteria by host neutrophils.

Authors:  Kathrin Westphal; Sara Leschner; Jadwiga Jablonska; Holger Loessner; Siegfried Weiss
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

9.  Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium.

Authors:  David C Binder; Ainhoa Arina; Frank Wen; Tony Tu; Ming Zhao; Robert M Hoffman; Derek A Wainwright; Hans Schreiber
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

10.  Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha.

Authors:  Sara Leschner; Kathrin Westphal; Nicole Dietrich; Nuno Viegas; Jadwiga Jablonska; Marcin Lyszkiewicz; Stefan Lienenklaus; Werner Falk; Nelson Gekara; Holger Loessner; Siegfried Weiss
Journal:  PLoS One       Date:  2009-08-20       Impact factor: 3.240
  10 in total
  2 in total

Review 1.  Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities.

Authors:  Mansour Sedighi; Abed Zahedi Bialvaei; Michael R Hamblin; Elnaz Ohadi; Arezoo Asadi; Masoumeh Halajzadeh; Vahid Lohrasbi; Nima Mohammadzadeh; Taghi Amiriani; Marcela Krutova; Abolfazl Amini; Ebrahim Kouhsari
Journal:  Cancer Med       Date:  2019-04-05       Impact factor: 4.452

Review 2.  Innovative Approaches of Engineering Tumor-Targeting Bacteria with Different Therapeutic Payloads to Fight Cancer: A Smart Strategy of Disease Management.

Authors:  Khaled S Allemailem
Journal:  Int J Nanomedicine       Date:  2021-12-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.